Transmural Care for Prostate cancer

Initiator: Catharina Wilhelmina Hospital (CWZ)NijmegenPrimary Sponsor/Performer: Radboud University Nijmegen Medical centerOther performers: CWZ in Nijmegen, Maashospital Pantein in Boxmeer0 sites200 target enrollmentTBD

ConditionsProstate cancer, transmural care, decision aid, SDM, Follow-up care, Substitution, Family doctors or General practitioners, Prostaatkanker, Keuzehulp, Samenwerking tussen eerste lijn en tweede lijn.

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Prostate cancer, transmural care, decision aid, SDM, Follow-up care, Substitution, Family doctors or General practitioners, Prostaatkanker, Keuzehulp, Samenwerking tussen eerste lijn en tweede lijn.
Sponsor: Initiator: Catharina Wilhelmina Hospital (CWZ)NijmegenPrimary Sponsor/Performer: Radboud University Nijmegen Medical centerOther performers: CWZ in Nijmegen, Maashospital Pantein in Boxmeer
Enrollment: 200
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Initiator: Catharina Wilhelmina Hospital (CWZ)NijmegenPrimary Sponsor/Performer: Radboud University Nijmegen Medical centerOther performers: CWZ in Nijmegen, Maashospital Pantein in Boxmeer

Eligibility Criteria

Inclusion Criteria

•1\. Healthy men who consider PSA testing.
•2\. Men who had prostatectomy for localized prostate cancer

Exclusion Criteria

•Insufficient knowledge of the Dutch language.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting

Phase 1

Response evaluation with 68Ga-PSMA PET of metastatic prostate cancer castration resistant patients in treatment with 223RaCl2Patients mCRPC eligible to treatment with 223RaCl2MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10005993Term: Bone metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10036223Term: Positron emission tomographySystem Organ Class: 100000004848MedDRA version: 21.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]

EUCTR2017-001395-38-ITAZIENDA USL DELLA VALLE D'AOSTA50

Completed

Phase 1

Radionuclide therapy using Lutetium-177 prostate specific membrane antigen (PSMA): a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)Prostate CancerCancer - Prostate

ACTRN12615000912583Peter MacCallum Cancer Centre30

Not yet recruiting

Not Applicable

PRO-Health – A prostate cancer specific healthy eating and exercise program

ACTRN12624000874516Deakin University50

Recruiting

Phase 1

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 TrialProstate cancerTherapeutic area: Diseases [C] - Neoplasms [C04]

CTIS2022-501551-90-00Gasthuiszusters Antwerpen493

Recruiting

Not Applicable

Evaluation of information provision and treatment decision making for men with early-stage prostate cancer.Prostate cancer, prostaatkanker

NL-OMON22128Tilburg University, St. Elisabeth Hospital400